Order 30 mg Hysingla ER oral tablet extended release Online
Extended-release tablets of HYSINGLA ER (hydrocodone bitartrate) are available in 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg, and 120 mg film-coated tablets for oral administration. The bitartrate salt quantity of hydrocodone per tablet is described by the tablet strengths.
An opioid agonist is hydrocodone bitartrate. 4,5-epoxy-3-methoxy-17methylmorphinan-6-one tartrate (1:1) hydrate is its chemical name (2:5). Order 30 mg Hysingla ER oral tablet extended release Online
Fine white crystals or a crystalline powder of hydrocodone bitartrate are available. Light has an impact on it. Water is soluble, alcohol is marginally soluble, while ether and chloroform are insoluble.
Butylated Hydroxytoluene (BHT, a Polyethylene Oxide additive), Hydroxypropyl Cellulose, Macrogol/PEG 3350, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Oxide, Polysorbate 80, Polyvinyl Alcohol, Talc, Titanium Dioxide, and Black Ink are the inactive ingredients in the 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg, and 120 mg tablets
Iron Oxide Yellow and FD&C Blue #2 Aluminum Lake/Indigo Carmine Aluminum Lake are also present in the 20 mg tablets.
Iron Oxide Yellow is also present in the 30 mg pills.
Iron Oxide Yellow, Iron Oxide Red, and Iron Oxide Black are also present in the 40 mg pills.
Iron Oxide Yellow and Iron Oxide Red are also present in the 60 mg pills.
Iron Oxide Red is also present in the 80 mg pills.
FD&C Blue #2 Aluminum Lake is also present in the 100 mg pills.
Shellac Glaze (in Ethanol), Isopropyl Alcohol, Iron Oxide Black, N-Butyl Alcohol, Propylene Glycol, and Ammonium Hydroxide are among the ingredients in black ink.
HYSINGLA ER is used to relieve pain that is severe enough to require daily, around-the-clock opioid medication for a lengthy period of time and for which other treatments are ineffective. Order 30 mg Hysingla ER oral tablet extended release Online
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and the increased risks of overdose and death with extended-release opioid formulations [see WARNINGS AND PRECAUTIONS], use HYSINGLA ER only in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise be insufficient to provide adequate pain management.
As-needed (prn) analgesia is not recommended with HYSINGLA ER.
Only logged in customers who have purchased this product may leave a review.